The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

As of 2021–2022, approximately 74% of U.S. adults aged 20 and older were classified as overweight or obese, with 42.1% ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

A study of real-world and virtual patients suggests that a less frequent dosing of glucagon-like peptide 1 receptor agonists ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Diabetes, a chronic condition that occurs when the blood sugar level gets too high, may lead to weight loss or weight gain.

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

In the late 2010s, Novo Nordisk shelved a weekly obesity treatment that targeted three hormones at once, though it caused ...

U.K. regulators issued guidance on Thursday, warning weight loss and diabetes medications may weaken the effectiveness of ...